glp 1 drops McKee's proposed FY2027 budget GLP-1 drugs for weight loss from Medicaid • Rhode Island Current GLP-1 use peaks in middle

n = 39 in the conventional arm) who completed 5.4 years of median follow-up underwent vibration-controlled transient elastography (FibroScan) to provide evidence of steatosis (controlled attenuation parameter (CAP)) and fibrosis [liver stiffness measurement (LSM)], while 42 participants (25 in conventional and 17 in triple therapy arms) eventually underwent MRI-PDFF to estimate liver fat content [128]

The winning approach isnt picking a drugits designing a system: start with orals where appropriate, reserve high-cost injectables for highest-risk members, and plan for step-up (and step-down) pathways as newer therapies emerge

Mali, G., Ahuja, V

A persons body mass index (BMI) is used as a screening tool for overweight and obesity

No single therapy addresses all hallmarks

However, it is crucial to understand that microdosing GLP-1 is not an evidence-based practice and lacks formal clinical trial data supporting its efficacy or safety